A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
Status:
Recruiting
Trial end date:
2026-12-17
Target enrollment:
Participant gender:
Summary
The primary objective of this post-marketing study is to assess the safety and tolerability
of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate
plaque psoriasis.